+39%

est. 2Y upside i

HealthcareSeries B

Rank

#2301

Sector

Medical Devices, Biotechnology, Healthcare

Est. Liquidity

~4Y

Data Quality

Data: Medium

Axio Biosolutions presents a high-risk equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (15%)+300%

Axio's patented Chitosan technology gains significant market traction, particularly with the recent FDA clearance for Axiostat Patch for Vascular Bleeding Control, driving strong adoption in both advanced wound care and hemostatic dressings. Revenue accelerates to $20M+ by 2028, justifying a $105M valuation (3x current estimate), leading to a 500% upside for common stock holders after accounting for liquidation preferences.

Base (35%)+125%

Axio maintains its niche in specialized wound care and hemostatic products, leveraging its regulatory approvals and existing customer base like the Indian Armed Forces. Growth stabilizes to modest positive rates, reaching $5-7M in revenue by 2028. An acquisition at a $52.5M valuation (1.5x current estimate) would provide a 125% return for common stock holders after preferences.

Bear (50%)-100%

The negative growth trend persists, and large incumbents with greater resources and distribution channels (e.g., 3M, J&J, Baxter) intensify competition, limiting Axio's market penetration. Despite recent FDA clearance, the company struggles to scale, leading to a down round or acquisition below the $21M liquidation preference, resulting in a 100% loss for common stock holders.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Total funding of $21M represents 60% of the estimated $35M current valuation, indicating a significant liquidation preference ahead of common stock holders.

Dilution Risk

high

With negative growth and relatively low revenue, the company may require additional funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Axio Biosolutions' equity.

Questions to Ask at the Interview

Strategic questions based on Axio's data — designed to show you've done your homework.

  • 1

    “Given the reported -17% YoY revenue growth, what are the specific strategies and milestones in place to reverse this trend and achieve significant revenue acceleration over the next 12-24 months?”

  • 2

    “With large incumbents like 3M and Johnson & Johnson in the market, how does Axio plan to leverage its specialized Chitosan technology and recent FDA clearances to capture and defend market share effectively?”

  • 3

    “Considering the Series B2 funding and the current revenue scale, what is the company's realistic timeline and strategy for a liquidity event (e.g., acquisition, IPO), and how is employee equity structured to ensure meaningful returns given the preference stack?”

Community

Valuation Sentiment

Our model estimates +39% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.